Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 2
2007 1
2008 1
2009 3
2010 1
2011 1
2012 3
2013 3
2014 2
2015 4
2016 3
2017 3
2018 3
2019 6
2020 8
2021 10
2022 8
2023 13
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Results by year

Filters applied: . Clear all
Page 1
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M; OPTIMISMM trial investigators. Richardson PG, et al. Among authors: robak p. Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13. Lancet Oncol. 2019. PMID: 31097405 Clinical Trial.
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Grosicki S, Simonova M, Spicka I, Pour L, Kriachok I, Gavriatopoulou M, Pylypenko H, Auner HW, Leleu X, Doronin V, Usenko G, Bahlis NJ, Hajek R, Benjamin R, Dolai TK, Sinha DK, Venner CP, Garg M, Gironella M, Jurczyszyn A, Robak P, Galli M, Wallington-Beddoe C, Radinoff A, Salogub G, Stevens DA, Basu S, Liberati AM, Quach H, Goranova-Marinova VS, Bila J, Katodritou E, Oliynyk H, Korenkova S, Kumar J, Jagannath S, Moreau P, Levy M, White D, Gatt ME, Facon T, Mateos MV, Cavo M, Reece D, Anderson LD Jr, Saint-Martin JR, Jeha J, Joshi AA, Chai Y, Li L, Peddagali V, Arazy M, Shah J, Shacham S, Kauffman MG, Dimopoulos MA, Richardson PG, Delimpasi S. Grosicki S, et al. Among authors: robak p. Lancet. 2020 Nov 14;396(10262):1563-1573. doi: 10.1016/S0140-6736(20)32292-3. Lancet. 2020. PMID: 33189178 Clinical Trial.
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.
Dytfeld D, Wróbel T, Jamroziak K, Kubicki T, Robak P, Walter-Croneck A, Czyż J, Tyczyńska A, Druzd-Sitek A, Giannopoulos K, Nowicki A, Szczepaniak T, Łojko-Dankowska A, Matuszak M, Gil L, Puła B, Rybka J, Majcherek M, Usnarska-Zubkiewicz L, Szukalski Ł, Końska A, Zaucha JM, Walewski J, Mikulski D, Czabak O, Robak T, Lahoud OB, Zonder JA, Griffith K, Stefka A, Major A, Derman BA, Jakubowiak AJ. Dytfeld D, et al. Among authors: robak p. Lancet Oncol. 2023 Feb;24(2):139-150. doi: 10.1016/S1470-2045(22)00738-0. Epub 2023 Jan 12. Lancet Oncol. 2023. PMID: 36642080 Free PMC article. Clinical Trial.
Atypical Chronic Lymphocytic Leukemia-The Current Status.
Robak T, Krawczyńska A, Cebula-Obrzut B, Urbaniak M, Iskierka-Jażdżewska E, Robak P. Robak T, et al. Among authors: robak p. Cancers (Basel). 2023 Sep 5;15(18):4427. doi: 10.3390/cancers15184427. Cancers (Basel). 2023. PMID: 37760396 Free PMC article. Review.
Drug resistance in multiple myeloma.
Robak P, Drozdz I, Szemraj J, Robak T. Robak P, et al. Cancer Treat Rev. 2018 Nov;70:199-208. doi: 10.1016/j.ctrv.2018.09.001. Epub 2018 Sep 4. Cancer Treat Rev. 2018. PMID: 30245231 Review.
Emerging antibody-drug conjugates for treating lymphoid malignancies.
Wolska-Washer A, Robak P, Smolewski P, Robak T. Wolska-Washer A, et al. Among authors: robak p. Expert Opin Emerg Drugs. 2017 Sep;22(3):259-273. doi: 10.1080/14728214.2017.1366447. Epub 2017 Aug 28. Expert Opin Emerg Drugs. 2017. PMID: 28792782 Review.
Comparative Effectiveness of Intracranial Pressure Monitoring on 6-Month Outcomes of Critically Ill Patients With Traumatic Brain Injury.
Nattino G, Gamberini L, Brissy O, Carrara G, Chesnut R, Chiarini V, Chieregato A, Csomos A, Fleming JM, Gradisek P, Kaps R, Kyprianou T, Lazar I, Lemeshow S, Mikaszewska-Sokolewicz M, Paci G, Rossi C, Temkin N, Xirouchaki N, Giugni A, Bertolini G; CREACTIVE Consortium. Nattino G, et al. JAMA Netw Open. 2023 Sep 5;6(9):e2334214. doi: 10.1001/jamanetworkopen.2023.34214. JAMA Netw Open. 2023. PMID: 37755832 Free PMC article.
Anti-CD37 antibodies for chronic lymphocytic leukemia.
Robak T, Robak P. Robak T, et al. Among authors: robak p. Expert Opin Biol Ther. 2014 May;14(5):651-61. doi: 10.1517/14712598.2014.890182. Epub 2014 Feb 20. Expert Opin Biol Ther. 2014. PMID: 24555705 Review.
73 results